[Current surgical therapy for malignant pleural mesothelioma]

Area of Science:

• Oncology
• Thoracic Surgery

Background:

• Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis.
• Palliative care alone results in a median survival time (MST) of 8.9 months.
• The diffuse and infiltrative growth pattern of MPM complicates radical surgical tumor removal.

Purpose of the Study:

• To evaluate the efficacy of different treatment modalities for malignant pleural mesothelioma.
• To compare survival outcomes between palliative care, surgery alone, and chemotherapy.

Main Methods:

• Review of median survival times (MST) for different treatment approaches.
• Analysis of outcomes for palliative care only, surgery only, and pemetrexed/cisplatin chemotherapy.
• Consideration of opinions regarding invasive surgical procedures like extrapleural pneumonectomy (EPP).

Main Results:

• Palliative care only: MST 8.9 months.
• Surgery only: MST 13 months.
• Pemetrexed/cisplatin chemotherapy: MST 12.1 months.

Conclusions:

• Radical tumor removal is challenging in MPM due to its growth pattern.
• Current standard of care involves multidisciplinary treatment combining surgery, chemotherapy, and radiation therapy.
• The role of invasive surgery like EPP is debated.